Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Expert Opinion on Drug Safety|March 10, 2004
Molecular profiling approaches for identifying novel biomarkersWendy J Bailey, Roger Ulrich
Nature Reviews. Drug Discovery|July 18, 2002
Toxicogenomics and drug discovery: will new technologies help us produce better drugs?Roger Ulrich, Stephen H Friend
International Journal of Cardiology|February 3, 2005
Influence of intensive coronary care acoustics on the quality of care and physiological state of patientsInger Hagerman, Gundars Rasmanis, Vanja Blomkvist, et al.
Pharmacogenetics and Genomics|July 19, 2006
Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell linesDylan P Hartley, Xudong Dai, Jocelyn Yabut, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2002
The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone classRichard J Sciotti, Marina Pliushchev, Paul E Wiedeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse ModelCarsten U Niemann, Helena I Mora-Jensen, Eman L Dadashian, et al.
Diabetes|July 30, 2002
Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesisCristina M Rondinone, James M Trevillyan, Jill Clampit, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 9, 2017
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency ProfileTjeerd Barf, Todd Covey, Raquel Izumi, et al.
Virology|May 22, 2012
Chronic immune activation is a distinguishing feature of liver and PBMC gene signatures from HCV/HIV coinfected patients and may contribute to hepatic fibrogenesisAngela L Rasmussen, I-Ming Wang, Margaret C Shuhart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic LeukemiaSarah E M Herman, Arnau Montraveta, Carsten U Niemann, et al.
Pageof 2